AU2006210715A1 - New uses of dinucleotide polyphosphate derivatives - Google Patents

New uses of dinucleotide polyphosphate derivatives Download PDF

Info

Publication number
AU2006210715A1
AU2006210715A1 AU2006210715A AU2006210715A AU2006210715A1 AU 2006210715 A1 AU2006210715 A1 AU 2006210715A1 AU 2006210715 A AU2006210715 A AU 2006210715A AU 2006210715 A AU2006210715 A AU 2006210715A AU 2006210715 A1 AU2006210715 A1 AU 2006210715A1
Authority
AU
Australia
Prior art keywords
compound
appch
ppa
formula
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006210715A
Other languages
English (en)
Inventor
Natalya Lozovaya
Andrew David Miller
Julian Alexander Tanner
Michael Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMUTHES
Original Assignee
IMUTHES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IMUTHES filed Critical IMUTHES
Publication of AU2006210715A1 publication Critical patent/AU2006210715A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2006210715A 2005-02-03 2006-02-01 New uses of dinucleotide polyphosphate derivatives Abandoned AU2006210715A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0502250.4A GB0502250D0 (en) 2005-02-03 2005-02-03 Use
GB0502250.4 2005-02-03
PCT/GB2006/000343 WO2006082397A1 (en) 2005-02-03 2006-02-01 New uses of dinucleotide polyphosphate derivatives

Publications (1)

Publication Number Publication Date
AU2006210715A1 true AU2006210715A1 (en) 2006-08-10

Family

ID=34307930

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006210715A Abandoned AU2006210715A1 (en) 2005-02-03 2006-02-01 New uses of dinucleotide polyphosphate derivatives

Country Status (8)

Country Link
US (1) US20080319184A1 (enExample)
EP (1) EP1846004A1 (enExample)
JP (1) JP2008528665A (enExample)
CN (1) CN101180066A (enExample)
AU (1) AU2006210715A1 (enExample)
CA (1) CA2596959A1 (enExample)
GB (1) GB0502250D0 (enExample)
WO (1) WO2006082397A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201209244D0 (en) * 2012-05-25 2012-07-04 Globalacorn Ltd Compositions
GB201320962D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
GB201320959D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
KR102504764B1 (ko) * 2017-06-21 2023-03-02 주식회사 종근당 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법
WO2021123388A1 (en) * 2019-12-20 2021-06-24 Nuvamid Sa Novel nicotinamide di-nucleotide derivatives and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5681823A (en) * 1996-05-02 1997-10-28 Prp Inc. P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
ES2264197T3 (es) * 1997-02-06 2006-12-16 Inspire Pharmaceuticals, Inc. Dinucleotidos y sus usos.
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
GB9711848D0 (en) * 1997-06-06 1997-08-06 William Harvey Research Limite Treatment and prophylaxis of infraction
WO1999003480A1 (en) * 1997-07-17 1999-01-28 William Harvey Research Limited Use of adenosine tri- or tetra-phosphates and their analogues for the treatment of cerebral infarction
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
GB2394419B (en) * 2001-06-25 2005-09-07 Inspire Pharmaceuticals Inc Joint lubrication with p2y purinergic receptor agonists
CN1612739A (zh) * 2001-11-06 2005-05-04 印斯拜尔药品股份有限公司 治疗或预防炎性疾病的方法
US7203743B2 (en) * 2001-12-28 2007-04-10 Nortel Networks Limited Hierarchical tree-based protection scheme for mesh networks

Also Published As

Publication number Publication date
GB0502250D0 (en) 2005-03-09
WO2006082397A1 (en) 2006-08-10
CN101180066A (zh) 2008-05-14
EP1846004A1 (en) 2007-10-24
JP2008528665A (ja) 2008-07-31
CA2596959A1 (en) 2006-08-10
US20080319184A1 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
Cui et al. Mdivi-1 protects against ischemic brain injury via elevating extracellular adenosine in a cAMP/CREB-CD39-dependent manner
Sperlágh et al. The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects
Fields et al. Purinergic signalling in neuron–glia interactions
Lopes et al. Cross talk between A1 and A2A adenosine receptors in the hippocampus and cortex of young adult and old rats
Carta et al. The muscle relaxant thiocolchicoside is an antagonist of GABAA receptor function in the central nervous system
ES2646835T3 (es) Compuestos, composiciones y procedimientos útiles para la movilización del colesterol
Martire et al. Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia
Kennedy P2X receptors: targets for novel analgesics?
Jackson Discovery and roles of 2′, 3′-cAMP in biological systems
Irnich et al. ATP stimulates peripheral axons in human, rat and mouse—differential involvement of A2B adenosine and P2X purinergic receptors
US8618074B2 (en) GPCR enhanced neuroprotection to treat brain injury
Coppi et al. Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices
AU2006210715A1 (en) New uses of dinucleotide polyphosphate derivatives
Rathbone et al. AIT-082 as a potential neuroprotective and regenerative agent in stroke and central nervous system injury
Burnstock Purinergic signalling in development
Darstein et al. Strychnine-sensitive glycine receptors inducing [3H]-acetylcholine release in rat caudatoputamen: a new site of action of ethanol?
Floran et al. Interactions between adenosine A2A and dopamine D2 receptors in the control of [3H] GABA release in the globus pallidus of the rat
Melnik et al. Diadenosine polyphosphate analog controls postsynaptic excitation in CA3-CA1 synapses via a nitric oxide-dependent mechanism
Schmidt et al. Spinal mechanisms of antinociceptive action caused by guanosine in mice
RU2614759C1 (ru) Анальгетический пептид из морской анемоны
Narimatsu et al. Blockers of adenosine A1, but not muscarinic acetylcholine, receptors improve excessive extracellular glutamate-induced synaptic depression
Cho et al. P2X and P2Y receptors mediate contraction induced by electrical field stimulation in feline esophageal smooth muscle
Verkhratsky et al. Adenosine triphosphate (ATP) as a neurotransmitter
Sala et al. Polydeoxyribonucleotide (defibrotide) protects against post-ischemic behavioral, electroencephalographic and neuronal damage in the gerbil
Numagami et al. Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application